Abstract:

Objective   To assess the effect of administration of tirofiban and fondaparinux during percutaneous coronary intervention (PCI) in patients with non-STsegment elevation acute coronary syndrome (NSTEACS). Methods   Two hundred and eleven NSTEACS patients were continuously selected and randomly assigned into experimental group (105 patients, accepting perioperational administration of tirofiban and fondaparinux) and control group (106 patients, only accepting perioperational administration of fondaparinux). We observed the corrected TIMI frame count (CTFC), myocardial necrosis markers and MACE of 6 months after PCI. Results   Compared with control group, experimental group was significantly improved in post-PCI CTFC. The elevation of myocardial necrosis markers 24 hours after PCI and incidence of MACE 6 months after PCI were significantly lower in experimental group. No significant difference was found in hemorrhage occurrence between the two groups. Conclusion   Compared with only administration of fondaparinux, administration of tirofiban and fondaparinux during PCI in NSTEACS patients improves myocardial perfusion and CTFC, and reduces post-PCI myocardial injury and incidence of MACE after PCI.

Key words: Acute coronary syndrome; Angioplasty; Tirofiban; Fondaparinux